## **Amendments to the Specification**

Please amend the Specification to insert a new first paragraph, immediately following the title, to claim priority under 35 U.S.C.§119(e), as follows:

"This U.S. national stage application of International Application PCT/US2005/005418, filed February 18, 2005, claims priority to U.S. provisional application Serial Number 60/547,681, filed February 25, 2004."

Furthermore, please add as a new last page of the Specification, after the Claims, the following abstract, which abstract is the same as filed with the PCT application:

## **ABSTRACT**

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT<sub>2C</sub> receptor agonists for the treatment of 5-HT<sub>2C</sub> associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:

$$R^7$$
 $R^8$ 
 $R^9$ 
 $R^1$ 
 $R^4$ 
 $R^2$ 
 $R^2$ 
 $R^3$ 
 $R^4$ 

where:

 $R^6$  is  $-C = C - R^{10}$ ,  $-O - R^{12}$ ,  $-S - R^{14}$ , or  $-NR^{24}R^{25}$ ;

and other substituents are as defined in the specification.